globe usa magnifying-glass checkbox g-plus rss youtube fb-round connect-with-us-in connect-with-us-twitter youtube2 facebook linkedin twitter
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol

The PIONIR Study

  • Multi center, post market, non-randomized, prospective, single arm clinical study evaluating the safety and effectiveness of NIRxcell stent
  • 278 patients enrolled at 16 sites from Europe and Israel
  • De novo stenotic lesions in native coronary arteries
  • Primary endpoint: TVF at 270 days
  • Result: TVF at 270 days was 8.7% (significantly lower than the performance goal of 16.5%)